28 Mar 2025 • Serum fibroblast growth factor 23 (FGF23) and dipeptidyl peptidase 4 (DPP4) were identified as key biomarkers for assessing coronary artery disease (CAD) severity and prognosis in patients with type 2 diabetes mellitus (T2DM).

FGF23 and DPP4 levels were significantly higher in those with both T2DM and coronary heart disease (CHD). Patients with poor prognosis exhibited elevated biomarker levels, greater left atrial diameter, and reduced ejection fraction.

A combined predictive model using both markers outperformed individual assessments (AUC = 0.921) in managing diabetic patients with CAD.

Source: Dovepress | Read Full Story